Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...
Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...
Contract Pharma1d
FDA Grants Priority Review to Boehringer Ingelheim’s NDA for Zongertinib
The U.S. Food and Drug Administration (FDA) has granted Priority Review to Boehringer Ingelheim’s new drug application for zongertinib (BI 1810631) for the treatment of adult patients with ...
GlobalData on MSN19h
FDA grants priority review for Boehringer’s zongertinib NDA in NSCLC
Priority review illustrates the urgent need in this patient population and the possibility for zongertinib to be a groundbreaking innovation for patients with limited treatment ...
pharmaphorum4d
Roche, Boehringer tap biosensor firms for patient studies
Roche and Boehringer Ingelheim have both formed partnerships with tech companies this week to develop and deploy wearable biosensor technology for use in clinical trials and patient monitoring ...
Contract Pharma1d
Biologics R&D: Derisking Scale-up and Tox Supply
As a biologics CDMO focused on developing and manufacturing recombinant protein products using mammalian cell culture ...
pharmaphorum2d
Boehringer preps phase 3 for dual-action obesity drug
Armed with results from a phase 2 trial, Boehringer Ingelheim has said it will take its obesity drug candidate survodutide into a phase 3 programme later this year. The glucagon/GLP-1 receptor ...
precisionmedicineonline1d
FDA Accepts Boehringer Ingelheim's New Drug Application for HER2-Targeted Therapy in NSCLC
In a Phase Ib trial, 71 percent of patients responded to zongertinib and lived a median six months before disease progression or death.